Baird Medical Expands Global Reach with Regulatory Clearance in Argentina

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced regulatory clearance of its minimally invasive Microwave Ablation systems in Argentina on March 12, 2026. This approval expands the company’s international certifications beyond the United States FDA to include Indonesia, Malaysia, and Vietnam.

According to the company, Baird Medical is pursuing formal registration in Egypt, Sri Lanka, the Philippines, Pakistan, and other markets to broaden global patient access to its MWA technology.

Positive

• Argentina regulatory clearance adds a new international market
• Portfolio of approvals now includes FDA plus Indonesia, Malaysia, and Vietnam
• Active registration pipeline in Egypt, Sri Lanka, Philippines, Pakistan and others

Negative

• None.

News Market Reaction – BDMD

-14.34%

19 alerts

-14.34% Session close to close

+7.3% Peak Tracked

-11.4% Trough Tracked

$96.95M Market Cap

0.2x Rel. Volume

In the Mar 12 session, BDMD declined 14.34%, reflecting a significant negative market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -11.4% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -14.3% in the session following this news. A negative reaction despite positive-so...

Analysis

The stock dropped -14.3% in the session following this news. A negative reaction despite positive-sounding international clearance would fit past instances where promotional expansion news coincided with declines, such as prior U.S. conference updates that saw drops of more than 5%. The backdrop includes registered resale shares that could weigh on sentiment. Mixed historical responses to marketing-driven news suggest that pullbacks have not always reflected changes in the fundamental opportunity.

Key Figures

Registered warrant shares: 11,500,000 ordinary shares Warrant exercise price: US$11.50 per share Registered resale shares: 34,415,562 ordinary shares +5 more

8 metrics

Registered warrant shares 11,500,000 ordinary shares Ordinary shares issuable upon exercise of public warrants

Warrant exercise price US$11.50 per share Exercise price for public warrants in 424B3 filing

Registered resale shares 34,415,562 ordinary shares Ordinary shares registered for resale by existing shareholders

Reference share price US$1.63 Nasdaq share price on December 4, 2025 cited in 424B3

Resale ownership share 70.9% Resale shares as percentage of shares outstanding, assuming conversions

Current price $2.58 Pre-news trading price vs. 52-week range

52-week high $7.2616 Upper end of 52-week trading range

52-week low $0.757 Lower end of 52-week trading range

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 09	U.S. expansion showcase	Positive	-7.4%	Showcased MWA technology at NASIT 2026 to support U.S. expansion.
Mar 04	AI software registration	Positive	+38.1%	Announced AI-driven surgical software and began major-market registrations.
Mar 02	Conference expansion push	Positive	-5.7%	Outlined U.S. expansion strategy at NASOIE 2026 with clinician engagement.
Feb 25	Clinical adoption update	Positive	+29.0%	Reported expanded U.S. clinical use of MWA for benign thyroid conditions.
Feb 19	Conference plans	Positive	+12.3%	Planned showcasing thyroid MWA solutions at three U.S. clinical conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been positive in tone, with mixed price reactions: some marketing and expansion updates saw strong gains, while others triggered notable pullbacks.

Recent Company History

Over the last few weeks, Baird Medical has focused on commercial expansion and technology advancement. It showcased minimally invasive microwave ablation solutions at multiple U.S. conferences, emphasized interventional thyroidology growth, and highlighted clinical adoption by U.S. physicians (Feb 25). On Mar 4, it announced completion of AI-driven surgical software and regulatory registrations in major markets, which drew a strong positive reaction. Subsequent U.S. expansion conference appearances saw share price pullbacks despite similarly promotional news.

Key Terms

microwave ablation (mwa), regulatory clearance, fda, minimally invasive, +1 more

5 terms

microwave ablation (mwa) medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

regulatory clearance regulatory

"today announced the regulatory clearance of its systems in Argentina"

Regulatory clearance is official permission from a government agency to market, sell, or use a product or service after it meets required safety, quality, or performance standards. For investors it matters because receiving clearance often unlocks revenue, lowers legal and commercial risk, and can materially change a company’s growth outlook—think of it like a driver’s license that legally allows a product to be driven onto the market.

fda regulatory

"portfolio of international certifications, which includes the United States FDA"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

minimally invasive medical

"expand patient access to highly effective, minimally invasive therapies worldwide"

Medical procedures described as minimally invasive use small cuts, flexible tubes or tiny cameras to treat or diagnose problems with far less cutting than traditional surgery — like using a keyhole instead of tearing down a wall. Investors care because these approaches can shorten hospital stays, lower complication rates and change equipment and reimbursement needs, which can speed adoption and reshape market demand for devices, supplies and services.

soft tissue medical

"address a wide variety of soft tissue conditions"

Soft tissue is the body's non-bony material—muscles, fat, tendons, ligaments, blood vessels and nerves—that supports movement, cushions organs and transmits signals and blood. For investors, soft tissue matters because many medical products, drugs and diagnostic tools target injuries, diseases or surgeries involving these tissues; think of it as the wiring and padding of a machine, where improvements or risks can change demand, costs, regulatory hurdles and reimbursement in healthcare markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 12, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This milestone drives the Company's international growth, supporting a broader mission to expand patient access to highly effective, minimally invasive therapies worldwide.

The Argentine approval strengthens Baird Medical's growing portfolio of international certifications, which includes the United States FDA, Indonesia, Malaysia, and Vietnam. Building on this progress, the Company is actively seeking formal registration across several major regions. With applications currently under review in Egypt, Sri Lanka, the Philippines, Pakistan, and other key international markets, Baird Medical is steadily advancing its regulatory pipeline to meet rising global demand. This continued expansion ensures that healthcare providers worldwide are equipped with the advanced tools needed to address a wide variety of soft tissue conditions.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-expands-global-reach-with-regulatory-clearance-in-argentina-302711933.html

SOURCE BDMD

FAQ

What does the March 12, 2026 Argentina clearance mean for Baird Medical (BDMD)?

It grants Baird Medical market entry in Argentina for its Microwave Ablation systems, expanding clinical availability. According to the company, this approval complements existing certifications and supports broader international growth and patient access to minimally invasive therapies.

Which countries already certify Baird Medical's MWA systems besides Argentina and the US (BDMD)?

Baird Medical's MWA systems are certified in Indonesia, Malaysia, and Vietnam in addition to Argentina and the United States. According to the company, these certifications form a growing international regulatory portfolio supporting global commercialization efforts.

Is Baird Medical (BDMD) pursuing further regulatory registrations after Argentina?

Yes. The company is actively seeking formal registrations in Egypt, Sri Lanka, the Philippines, Pakistan, and additional markets. According to the company, applications are currently under review to expand its global regulatory footprint.

How will Argentina approval affect Baird Medical's (BDMD) global strategy?

Argentina approval supports Baird Medical's strategy to broaden international patient access to MWA technology and scale commercial reach. According to the company, the clearance strengthens its global certification base and aids entry into new healthcare markets.

Will the Argentina clearance allow Argentine hospitals to use Baird Medical (BDMD) devices immediately?

Regulatory clearance permits commercial registration and eventual clinical use subject to local registration and distribution arrangements. According to the company, this milestone enables steps toward market entry and partnership with regional healthcare providers.

Does the Argentina approval change Baird Medical's (BDMD) product regulatory risk profile?

The approval modestly lowers risk by adding another national clearance to its regulatory record, but broader risk remains tied to pending reviews. According to the company, multiple approvals strengthen evidence of international regulatory acceptance for its technology.